VA
ATXS

VR Adviser’s Astria Therapeutics ATXS Stock Holding History

VR Adviser’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,457,348
Closed -$17.9M – 29
2025
Q3 		$17.9M Hold
2,457,348
– – 1.01% 24
2025
Q2 		$13.2M Hold
2,457,348
– – 0.99% 22
2025
Q1 		$13.1M Hold
2,457,348
– – 1.12% 19
2024
Q4 		$22M Sell
2,457,348
-1,001,297
-29% -$10.6M 1.51% 18
2024
Q3 		$38.1M Sell
3,458,645
-150,000
-4% -$1.67M 1.99% 18
2024
Q2 		$32.8M Hold
3,608,645
– – 2.09% 15
2024
Q1 		$50.8M Buy
3,608,645
+382,839
+12% +$4.77M 2.42% 14
2023
Q4 		$24.8M Buy
+3,225,806
New +$17.8M 1.7% 20
2022
Q2 		– Sell
-538,999
Closed -$3.62M – 29
2022
Q1 		$3.62M Hold
538,999
– – 0.59% 25
2021
Q4 		$2.9M Hold
538,999
– – 0.4% 25
2021
Q3 		$4.76M Sell
538,999
-1
-0% -$10 0.61% 24
2021
Q2 		$6.82M Buy
+539,000
New +$7M 0.83% 27

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VR Adviser's ATXS Position: Q4 2025 in Review

VR Adviser sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 2,457,348 shares — an estimated $17.9M sold.

VR Adviser first reported a position in ATXS in Q2 2021 and held it in 12 quarters. The position peaked at $50.8M in Q1 2024. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • VR Adviser reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • VR Adviser sold 2,457,348 Astria Therapeutics shares in Q4 2025, an estimated $17.9M.
  • VR Adviser first reported a position in Astria Therapeutics in Q2 2021 and held it in 12 quarters.
  • VR Adviser's Astria Therapeutics position peaked at $50.8M in Q1 2024.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on VR Adviser's 13F filing for Q4 2025, filed 17 Feb 2026.